Skip to main content Skip to main navigation menu Skip to site footer
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
Search
  • Register
  • Login
  1. Home /
  2. Archives /
  3. Vol 5 No 5S (2011)

Published: 2011-12-15

Editorial

  • Resistance and/or intolerance: one more chance!
    Luigia Luciano
    3-6
    • PDF

Case report

  • Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
    Sabina Russo, Giuseppa Penna, Arianna D’Angelo, Alessandro Allegra, Andrea Alonci, Caterina Musolino
    7-14
    • PDF
  • Efficacy of nilotinib in a patient in non-optimal response after imatinib treatment but in reduced compliance to the new drug
    Francesca Sassolini
    15-19
    • PDF
  • Complete Molecular Response due to nilotinib as III line treatment in a patient with CML and F317L point mutation of the Bcr-Abl kinase domain
    Maria Iovine, Giuseppe Monaco, Mario Troiano, Antonio Abbadessa
    21-25
    • PDF
  • Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
    Emilio Usala
    27-30
    • PDF
Information
  • For Readers
  • For Authors
  • For Librarians

METABOLIC SYNDROME. From Risk Factors to Management

Physicians can use the metabolic syndrome concept to guide focused lifestyle changes, lower blood pressure goals, and earlier intervention with aspirin, LDL-lowering drugs, and perhaps insulin-sensitizing medications. The comprehensive “ABCDE” approach presented in this book provides a memory tool for use in everyday clinical practice.

Printed version
Ebook version

Current Issue
  • Atom logo
  • RSS2 logo
  • RSS1 logo
About this Publishing System